Barinthus Biotherapeutics faces Nasdaq listing-rule breach as ADS trading halt nears Sept. 9

BRNS•2026-09-01

Court sanction and expected ADS trading halt

The England and Wales High Court sanctioned the Scheme of Arrangement and a share premium account capital reduction on Sept. 1, 2026.

The Scheme is now expected to become effective Sept. 9, 2026, and Nasdaq trading in the company’s American depositary shares is expected to halt before the open on Sept. 9, 2026.

Delisting and deregistration plans for the ADSs remain unchanged.

Nasdaq continued-listing issue tied to scheme of arrangement

Barinthus flagged a Nasdaq continued-listing issue tied to its planned Scheme of Arrangement and related corporate actions.

Sources

Barinthus Biotherapeutics faces Nasdaq listing-rule breach as ADS trading halt nears Sept. 9

Sec

Barinthus Biotherapeutics faces Nasdaq listing-rule breach as ADS trading halt nears Sept. 9

Court sanction and expected ADS trading halt

Nasdaq continued-listing issue tied to scheme of arrangement

Related News

AuthID gets Nasdaq notice after shares trade below $1 bid price requirement

OrthoPediatrics director, 10% owner David R. Pelizzon disposes of 336,831 common shares worth $7.76 million

Terawulf director Walter E. Carter disposes of 130,626 common shares worth $1.98 million

Sources

Barinthus Biotherapeutics faces Nasdaq listing-rule breach as ADS trading halt nears Sept. 9

California Resources outlines potential CO2 pipeline network to link California emitters with TerraVault storage sites

NovaBridge EVP Clinical Development Xu Cong Claire sells 3,282 shares for $0.79 each